Highly Potent Ghrelin Receptor Inhibitor - PF-05190457

REF #: 3199715
Short description

Highly Potent Ghrelin Receptor Inhibitor – PF-05190457

  • 95% HPLC purity
  • Orally available, potent and selective ghrelin receptor inhibitor
Quantity :
  • Procurenet Team Tshim Sha Tsui
    Hong Kong Hong Kong 3 years
Delivery options
  • 7 Days Return Back Policy
  • 2 Days Cancellation Policy
  • Ship Only

The product with the chemical name PF-05190457 is a highly potent and orally available ghrelin receptor inhibitor. It is classified as 1-[2-[(1R)-2,3-Dihydro-5-(6-methyl-4-pyrimidinyl)-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl]-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-ethanone. With a 95% high-performance liquid chromatography (HPLC) purity, it is a reliable product for researchers and scientists who are studying the ghrelin receptor and its role in various biological processes.

Ghrelin, also known as the "hunger hormone," is a peptide hormone secreted by the stomach. It plays a crucial role in regulating appetite, hunger, and energy balance. The ghrelin receptor is the target of PF-05190457, which inhibits its activity. By selectively binding to and inhibiting the ghrelin receptor, PF-05190457 has a strong therapeutic potential in the treatment of obesity and related metabolic disorders.

Features of PF-05190457:

  • Potency: Highly potent ghrelin receptor inhibitor, ensuring effective inhibition of the receptor's activity and downstream signaling.
  • Selectivity: Specifically targets the ghrelin receptor, minimizing off-target effects and providing a more focused therapeutic approach.
  • Oral availability: Designed for oral administration, offering convenience and ease of use for researchers and potential therapeutic applications.

The composition of PF-05190457 involves a complex molecular structure that is carefully designed to interact with the ghrelin receptor. It is composed of the following components:

  • Indenyl: Provides structural stability and contributes to the overall binding affinity to the ghrelin receptor.
  • Diazaspiro[3.5]nonane: Plays a crucial role in the compound's structural integrity and contributes to its selectivity towards the ghrelin receptor.
  • Pyrimidinyl: Enhances binding affinity to the ghrelin receptor, allowing for potent inhibition.
  • Imidazole-thiazole: Further enhances selectivity and binding affinity to the ghrelin receptor.

Potential applications of PF-05190457:

PF-05190457 holds significant promise as a therapeutic agent in the field of metabolic disorders, particularly as a treatment for obesity. By inhibiting the ghrelin receptor, which is intricately involved in appetite regulation, PF-05190457 can help reduce food intake and promote weight loss. Additionally, the compound's selectivity towards the ghrelin receptor minimizes the risk of off-target effects, making it a safer and more focused option for therapeutic interventions.

Researchers and scientists studying the ghrelin system and its role in metabolism and energy regulation will find PF-05190457 to be a valuable tool. Its highly potent inhibition of the ghrelin receptor allows for precise investigation of the receptor's functions and potential therapeutic applications. The compound's oral availability further enhances its utility, enabling easy administration and testing in various in vivo and in vitro models.

In summary, PF-05190457 is a highly potent, orally available, and selective ghrelin receptor inhibitor with a 95% HPLC purity. It offers researchers and scientists a reliable tool for studying the ghrelin system and its potential applications in metabolic disorders. With its carefully designed composition and specific binding to the ghrelin receptor, PF-05190457 has the potential to contribute to the development of novel therapeutic approaches for obesity and related conditions.

All categories